BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33813107)

  • 1. Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review.
    Martin C; Domingo C; Bottieau E; Buonfrate D; De Wit S; Van Laethem Y; Dauby N
    Clin Microbiol Infect; 2021 Jul; 27(7):958-967. PubMed ID: 33813107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity.
    Martin C; Florence E; Domingo C; Delforge M; De Wit S; Dauby N
    J Travel Med; 2022 Dec; 29(8):. PubMed ID: 35285913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
    Campi-Azevedo AC; Reis LR; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Antonelli LR; Fonseca CT; Costa-Pereira C; Souza-Fagundes EM; da Costa-Rocha IA; Mambrini JVM; Lemos JAC; Ribeiro JGL; Caldas IR; Camacho LAB; Maia MLS; de Noronha TG; de Lima SMB; Simões M; Freire MDS; Martins RM; Homma A; Tauil PL; Vasconcelos PFC; Romano APM; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA
    Front Immunol; 2019; 10():2192. PubMed ID: 31616412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
    Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of post-vaccination humoral immunity against yellow fever in children.
    de Noronha TG; de Lourdes de Sousa Maia M; Geraldo Leite Ribeiro J; Campos Lemos JA; Maria Barbosa de Lima S; Martins-Filho OA; Campi-Azevedo AC; da Silva Freire M; de Menezes Martins R; Bastos Camacho LA;
    Vaccine; 2019 Nov; 37(48):7147-7154. PubMed ID: 31590934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yellow fever vaccine for patients with HIV infection.
    Barte H; Horvath TH; Rutherford GW
    Cochrane Database Syst Rev; 2014 Jan; (1):CD010929. PubMed ID: 24453061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
    Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
    Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
    J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroconversion and persistence of neutralizing antibody response after yellow fever vaccination in patients with perinatally acquired HIV infection.
    Martin C; Domingo C; Hainaut M; Delforge M; De Wit S; Dauby N
    AIDS; 2023 Feb; 37(2):341-346. PubMed ID: 36541645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.
    Gotuzzo E; Yactayo S; Córdova E
    Am J Trop Med Hyg; 2013 Sep; 89(3):434-44. PubMed ID: 24006295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
    da Costa-Rocha IA; Machado KLLL; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; de Lima SMB; Miranda EH; Trindade GF; Casagrande TZ; Miyamoto ST; Deotti SC; Barbosa RVR; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Valim V; Martins-Filho OA
    Sci Rep; 2021 May; 11(1):10431. PubMed ID: 34001945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immunogenicity of primary yellow fever vaccination in infants and children: a systematic review, meta-analysis and meta-regression.
    Ferrara P; Losa L; Mantovani LG; Ambrosioni J; Agüero F
    J Travel Med; 2024 Apr; 31(3):. PubMed ID: 38438165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single shot of 17D vaccine may not confer life-long protection against yellow fever.
    Vasconcelos PF
    Mem Inst Oswaldo Cruz; 2018 Feb; 113(2):135-137. PubMed ID: 29185596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.
    Idoko OT; Domingo C; Tapia MD; Sow SO; Geldmacher C; Saathoff E; Kampmann B
    Front Immunol; 2020; 11():577751. PubMed ID: 33133096
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.
    Gonçalves AP; Almeida LT; Rezende IMd; Fradico JRB; Pereira LS; Ramalho DB; Pascoal Xavier MA; Calzavara Silva CE; Monath TP; LaBeaud AD; Drumond BP; Campi-Azevedo AC; Martins-Filho OA; Teixeira-Carvalho A; Alves PA;
    Microbiol Spectr; 2024 May; 12(5):e0370323. PubMed ID: 38511952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.
    Campi-Azevedo AC; de Araújo-Porto LP; Luiza-Silva M; Batista MA; Martins MA; Sathler-Avelar R; da Silveira-Lemos D; Camacho LA; de Menezes Martins R; de Lourdes de Sousa Maia M; Farias RH; da Silva Freire M; Galler R; Homma A; Ribeiro JG; Lemos JA; Auxiliadora-Martins M; Caldas IR; Elói-Santos SM; Teixeira-Carvalho A; Martins-Filho OA
    PLoS One; 2012; 7(12):e49828. PubMed ID: 23251351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
    Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
    Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients.
    Avelino-Silva VI; Miyaji KT; Hunt PW; Huang Y; Simoes M; Lima SB; Freire MS; Caiaffa-Filho HH; Hong MA; Costa DA; Dias JZ; Cerqueira NB; Nishiya AS; Sabino EC; Sartori AM; Kallas EG
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005219. PubMed ID: 27941965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.